Vaccination Response to an Ongoing Meningitis Outbreak: Uptake and Attitudes among Men Who Have Sex with Men in Los Angeles, CA

Paula Frew, Emory University
IHolloway
E Wu
J Gildner
V Fenimore

Journal Title: Open Forum Infectious Diseases
Volume: Volume 4, Number suppl_1
Publisher: California HIV/AIDS Policy Research Centers | 2017, Pages S418-S418
Type of Work: Article
Publisher DOI: 10.1093/ofid/ofx163.1046
Permanent URL: https://pid.emory.edu/ark:/25593/s6gff

Final published version: http://dx.doi.org/10.1093/ofid/ofx163.1046

Accessed December 30, 2017 11:36 AM EST
Disclosures. P. Vink, GSK, group of companies: Employee, Salary and stock options and stock granted.

1350. Vaccination Response to an Ongoing Meningitis Outbreak: Uptake and Attitudes Among Men Who Have Sex with Men in Los Angeles, CA
Ian Holloway, PhD, MSW, MPH, Elizabeth Wu, MPH1, Jennifer Gildner, MSPH1, Vincent Fenimore, PhD, M.D.E.2, Paula Frew, PhD, MA, MPH1,2,3, Pai-Hsin Ku, MD, MPH1,2,3, and Elyse E. Leidman, MD1,2,3,4,5
1Department of Behavioral Sciences and Health Education, Rollins School of Public Health, Emory University, Atlanta, Georgia; 2Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia; 3Department of Behavioral Sciences and Health Education, Rollins School of Public Health, Emory University, Atlanta, Georgia

Session: 152. Herpes Zoster Vaccine
Friday, October 6, 2017: 12:30 PM

Background. Men who have sex with men (MSM) are at high risk for invasive meningococcal disease (IMD). Following a 2016 IMD outbreak in Southern California, public health officials issued a Advisory that urged MSM to get vaccinated. We assessed IMD vaccination knowledge and behaviors among other factors. Chi-square and independent sample t-tests were used to determine bivariate associations. Statistically significant variables from bivariate analyses were included in a multivariate logistic regression model predicting MCV4 uptake.

Methods. From November 2016 through February 2017, we used venue-based sampling to recruit MSM in Los Angeles (N = 513). Eligible participants completed a 30-minute iPad survey that included items on MCV4 status, sexual behavior, vaccination knowledge and behaviors among other factors. Chi-square and independent sample t-tests were used to determine bivariate associations. Statistically significant variables from bivariate analyses were included in a multivariate logistic regression model predicting MCV4 uptake.

Results. Participants were young (M=33, SD=10) and racially/ethnically diverse: White (35.7%), Black/African American (14.6%), Hispanic (36.5%), Asian/Pacific Islander (4.1%), Other (9.2%). Reported MCV4 immunization among MSM (25.4%) and MSM living with HIV (37.7%) was low. Statistically significant correlates of MCV4 uptake were: male gender (aOR=2.71), younger age (aOR=2.21), believing MCV4 vaccination was important (aOR=3.45), having confidence in the MCV4 vaccine (aOR=5.43), and knowing someone who had received the vaccination (aOR=5.21).

Conclusion. MSMs perceived health risk, vaccine confidence, and knowledge of someone who received the MCV4 vaccine were important indicators of meningitis immunization in this outbreak context. Provider and public health education efforts may be enhanced by messages that emphasize personal health risks, the safety and efficacy of MCV4, and the importance of meningococcal vaccines for men's health. Popular opinion leader programs facilitated by someone who had been vaccinated are warranted to enhance MCV4 uptake.

Disclosures. All authors: No reported disclosures.

1351. Bivalent Norovirus VLP Vaccine Candidate in Older Adults: Impact of MPL and a Second Dose in a Randomized, Controlled, Double-Blind Clinical Trial
J. Sherwood, C. E. Cramer, P. Mendelman, A. Borkowski

Background. Acute norovirus (NoV) gastroenteritis may cause significant morbidity in healthy adults and can prove fatal in older subjects. We investigated the safety and immunogenicity in older adults of one or two doses of an intramuscular bivalent virus-like particle (VLP) vaccine candidate (genotypes GI.1 and multivalent GI.2-GII.4c) formulated with alum and with and without MPL (3-O-desacyl-4′-monophosphoryl lipid A) adjuvant.

Methods. In a phase II, double-blind, controlled trial, 294 healthy adults ≥ 60 years of age randomized to 4 equal groups received one or two immunizations 28 days apart. One dose groups received placebo (saline) on Day 1. Vaccine formulations contained 50μg GI.1 and 50μg GII.4c VLP antigens, with or without 15μg MPL adjuvant. A fifth group of 26 healthy 18–49 year-olds received one dose of MPL-free vaccine. Humoral immunity was assessed as ELISA positive antibody titers with Day 1 and Day 28 samples to vaccine strains. Safety was assessed as solicited local and systemic adverse events (AE) for 7 days after each vaccination.

Results. Marked increases in pan-Ig and HBGA to both genotypes occurred by Day 8 after first vaccination. Geometric mean titers were similar in magnitude in all groups and there were no clinically relevant differences in CMI responses or changes in antibody avidity were observed between groups to a single vaccine dose in 18–49 year-olds. No clinically relevant differences in CMI responses or changes in antibody avidity were observed between formulations. Both formulations were generally well tolerated, the most frequent reactions being mild pain at the injection site. No vaccine-related SAEs were reported.

Conclusion. Older adults aged over 60 years displayed immune responses to NoV VLP vaccines that were similar in healthy adults with no apparent signs of immunosenescence. These data support the further development of the MPL-free vaccine candidate in older adults.